menu
    • menu
    [{"orgOrder":0,"company":"Marinomed Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Carrageenan","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Marinomed Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"Marinomed Biotech \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Marinomed Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Marinomed Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Carrageenan","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Marinomed Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"Marinomed Biotech \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Marinomed Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Cebina","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Azelastine Hydrochloride","moa":"H1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cebina","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Cebina \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cebina \/ Inapplicable"},{"orgOrder":0,"company":"Panoptes Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"PP-OO1","moa":"DHODH","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Panoptes Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Panoptes Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Panoptes Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Themis Bioscience","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRIA","productType":"Vaccine","year":"2020","type":"Acquisition","leadProduct":"SARS-CoV-2 Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Themis Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Themis Bioscience \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Themis Bioscience \/ Merck & Co"},{"orgOrder":0,"company":"Themis Bioscience","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRIA","productType":"Vaccine","year":"2020","type":"Acquisition","leadProduct":"SARS-CoV-2 Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Themis Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Themis Bioscience \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Themis Bioscience \/ Merck & Co"},{"orgOrder":0,"company":"VALANX Biotech","sponsor":"Fina Biosolutions","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRIA","productType":"Vaccine","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"VALANX Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VALANX Biotech \/ Fina Biosolutions","highestDevelopmentStatusID":"4","companyTruncated":"VALANX Biotech \/ Fina Biosolutions"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            VALANX Biotech

                            Austria arrow
                            APGA Annual Conference
                            Not Confirmed

                            VALANX Biotech

                            Austria arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Fina Biosolutions

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            VALANX Biotech And Fina Biosolutions Launch ClickCRM for Vaccine R&D

                            Details : The licensing agreement will commercialize ready-to-conjugate vaccine carrier protein CRM197 enabling rapid development of conjugate vaccines such as the pneumococcal and meningococcal vaccines.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            October 29, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Fina Biosolutions

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Cebina

                            Austria arrow
                            APGA Annual Conference
                            Not Confirmed

                            Cebina

                            Austria arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Azelastine Hydrochloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CEBINA Reports Positive Findings on the Potency of Azelastine, a Widely Used Anti-Histamine, as Anti-Covid-19 ...

                            Details : The potent anti-SARS-CoV-2 activity of azelastine formulated in a nasal spray was demonstrated in an experimental reconstituted human nasal tissue model and was evident at a lower dose than present in commercially available products.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 17, 2020

                            Lead Product(s) : Azelastine Hydrochloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Marinomed Biotech

                            Austria arrow
                            APGA Annual Conference
                            Not Confirmed

                            Marinomed Biotech

                            Austria arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Carrageenan

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Marinomed Biotech AG Announces that Carragelose® has the Potential to Reduce the Risk of an Infection with SA...

                            Details : Data from Marinomed’s cell-culture study confirm that Carragelose® works in a dose-dependent manner to strongly reduce the infection of cells from the SARS-CoV-2 virus.

                            Product Name : Carragelose

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 16, 2020

                            Lead Product(s) : Carrageenan

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Themis Bioscience

                            Austria arrow
                            APGA Annual Conference
                            Not Confirmed

                            Themis Bioscience

                            Austria arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SARS-CoV-2 Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Merck & Co

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Merck Completes Acquisition of Themis

                            Details : An initial focus of this agreement is acceleration of the development of a measles vector-based SARS-CoV-2 vaccine candidate. This candidate is currently in pre-clinical development, and clinical studies are planned to start later in 2020.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            June 19, 2020

                            Lead Product(s) : SARS-CoV-2 Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Merck & Co

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Panoptes Pharma

                            Austria arrow
                            APGA Annual Conference
                            Not Confirmed

                            Panoptes Pharma

                            Austria arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PP-OO1

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Viennese Biotech Company Panoptes Pharma Gmbh Has A Promising Active Ingredient Against COVID-19

                            Details : Panoptes Pharma GmbH has been able to demonstrate that COVID-19 treatment with PP-001 inhibits excessive release of certain cytokines.

                            Product Name : PP-OO1

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 25, 2020

                            Lead Product(s) : PP-OO1

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth